Reduction of Platinum(IV) Prodrug Hemoglobin Nanoparticles with Deeply Penetrating Ultrasound Radiation for Tumor-Targeted Therapeutically Enhanced Anticancer Therapy
Ganghao Liang, Tumpa Sadhukhan, Samya Banerjee, Dongsheng Tang, Hanchen Zhang, Minhui Cui, Nicolás Montesdeoca, Johannes Karges*, Haihua Xiao*
Angew. Chem. Int. Ed. 2023, 62, e202301074
The development of PtIV prodrugs that are reduced into the therapeutically active PtII species within the tumor microenvironment has received much research interest. In order to provide spatial and temporal control over the treatment, there is a high demand for the development of compounds that could be selectively activated upon ihhadiation. Despite recent progress, the majority of PtIV complexes are excited with ultraviolet or blue light, limiting the use of such compounds to superficial application. To overcome this limitation, herein, the first example of PtIV prodrug nanoparticles that could be reduced with deeply penetrating ultrasound radiation is reported, enabling the treatment of deep-seated or large tumors. The nanoparticles were found to selectively accumulate inside a mouse colon carcinoma tumor upon intravenous injection and were able to eradicate the tumor upon exposure to ultrasound radiation. These findings highlight the high potential of this form of treatment for very large or deep-seated tumors and are expected to open new avenues for the treatment of cancer.
文献链接:https://onlinelibrary.wiley.com/doi/full/10.1002/anie.202301074